Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients

Research and Practice in Thrombosis and Haemostasis

the Dutch COVID & Thrombosis Coalition (DCTC)¹  Myrthe M. A. Toorop²  Qingui Chen²  Erik M. vanDriel³  K. Merijn Kant⁴  Evert deJonge⁵  Antonio Iglesias del Sol⁶  Coen vanGuldener⁷  Marco J. J. H. Grootenboers⁸  Frederikus A. Klok⁹  Fleur H. J. Kaptein⁹  Menno V. Huisman⁹  Gordon Chu⁹  Fleur Pals⁹  Sander J. E. Braken⁹  Milou A. M. Stals⁹  Suzanne C. Cannegieter⁹ 

[1] ;Department of Clinical Epidemiology Leiden University Medical Center Leiden The Netherlands;Department of Intensive Care Medicine Alrijne Hospital Leiderdorp The Netherlands;Department of Intensive Care Medicine Amphia Hospital Breda The Netherlands;Department of Intensive Care Medicine Leiden University Medical Center Leiden The Netherlands;Department of Internal Medicine Alrijne Hospital Leiderdorp The Netherlands;Department of Internal Medicine Amphia Hospital Breda The Netherlands;Department of Pulmonology Amphia Hospital Breda The Netherlands;Department of Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands;

关键词: COVID‐19;    human;    incidence;    influenza;    pneumonia;    thrombosis;   

DOI  :  10.1002/rth2.12496

来源: DOAJ

【 摘 要 】

Abstract Background Whereas accumulating studies on patients with coronavirus disease 2019 (COVID‐19) report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID‐19 patients compares to those observed in hospitalized patients with other viral pneumonias such as influenza is unknown. Objectives To assess the incidence of venous and arterial thrombotic complications in hospitalized patients with influenza as opposed to that observed in hospitalized patients with COVID‐19. Methods This was a retrospective cohort study; we used data from Statistics Netherlands (study period: 2018) on thrombotic complications in hospitalized patients with influenza. In parallel, we assessed the cumulative incidence of thrombotic complications—adjusted for competing risk of death—in patients with COVID‐19 in three Dutch hospitals (February 24 to April 26, 2020). Results Of the 13 217 hospitalized patients with influenza, 437 (3.3%) were diagnosed with thrombotic complications, versus 66 (11%) of the 579 hospitalized patients with COVID‐19. The 30‐day cumulative incidence of any thrombotic complication in influenza was 11% (95% confidence interval [CI], 9.4–12) versus 25% (95% CI, 18–32) in COVID‐19. For venous thrombotic (VTC) complications and arterial thrombotic complications alone, these numbers were, respectively, 3.6% (95% CI, 2.7–4.6) and 7.5% (95% CI, 6.3–8.8) in influenza versus 23% (95% CI, 16–29) and 4.4% (95% CI, 1.9–8.8) in COVID‐19. Conclusions The incidence of thrombotic complications in hospitalized patients with influenza was lower than in hospitalized patients with COVID‐19. This difference was mainly driven by a high risk of VTC complications in the patients with COVID‐19 admitted to the Intensive Care Unit. Remarkably, patients with influenza were more often diagnosed with arterial thrombotic complications.

【 授权许可】

Unknown